Today on Drug Discovery & Development
Rilzabrutinib on track for regulatory filing after ITP trial win
Sanofi revealed that its investigational BTK inhibitor rilzabrutinib notched a significant win in the LUNA 3 phase 3 study, hitting the primary endpoint of durable platelet response in adults with persistent or chronic immune thrombocytopenia (ITP). The study showed a significantly higher proportion of rilzabrutinib-treated patients achieved the platelet response goal compared to placebo in…New pharma and biotech manufacturing facilities and expansions announced worldwide for 2024
[Updated April 23, 2024] In the face of rising R&D costs and growing pricing pressures from payers, the pharma and biotech sectors continue to transform to adapt to an evolving landscape. While workforce reductions persist in 2024 for some companies, major players like AbbVie, AGC Biologics, Amgen, Novartis and Thermo Fisher Scientific are demonstrating confidence…Drug Discovery and Development See More >
New pharma and biotech manufacturing facilities and expansions announced worldwide for 2024
[Updated April 23, 2024] In the face of rising R&D costs and growing pricing pressures from payers, the pharma and biotech sectors continue to transform to adapt to an evolving landscape. While workforce reductions persist in 2024 for some companies, major players like AbbVie, AGC Biologics, Amgen, Novartis and Thermo Fisher Scientific are demonstrating confidence…
Sponsored Content See More >
Genomics/Proteomics See More >
Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosis
Endometriosis, a condition where endometrial tissue grows outside the uterus, has a strong genetic underpinning. A new study published in the Journal of Molecular Diagnostics sheds light on this connection. Researchers from a team including Genzeva, LumaGene, RYLTI Biopharma, Brigham & Women’s Hospital of Harvard University and QIAGEN Digital Insights used a unique approach in…
Unleashing a new frontier: The power of germline clinico-genomic data to drive therapeutic development
NVIDIA expands BioNeMo platform with new foundation models and microservices for AI-powered Drug Discovery
Navigating the cancer progression pathway with liquid biopsy
Microsoft and 1910 Genetics: AI-powered partnership targets billion-dollar savings and growth in drug discovery
Infectious Disease See More >
Best-selling pharmaceuticals of 2023 reveal a shift in pharma landscape
Note: This feature on the best-selling pharmaceuticals of 2023 was updated on March 27. Changes are possible as more data become available. Sales of drugs with more than one developer are added together (as in the case of the COVID-19 vaccine Comirnaty) unless one of those companies records the net sales for it, i.e., Dupixent.…
Lumen Bioscience cracks the code on spirulina as a biologics factory for c. diff, metabolic disease and more
Vaccine mega-trials: Rare behemoths in the vaccine trial landscape
Biden names 31 tech hubs: Here are 10 relevant to pharma and biotech
An overview of the RSV vaccine landscape: GSK aims to extend its approval of Arexvy?
Oncology See More >
FDA approves pair of therapies for rare pediatric cancers: Novartis’ Lutathera and Day One’s Ojemda
The FDA has signed off on two novel therapies targeting rare pediatric cancers. Novartis’ Lutathera targets aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in children 12 and up, while Day One Biopharma’s Ojemda (tovorafenib) tackles treatment-resistant BRAF-mutated relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation These approvals offer…